1. Home
  2. RFIL vs PEPG Comparison

RFIL vs PEPG Comparison

Compare RFIL & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RF Industries Ltd.

RFIL

RF Industries Ltd.

HOLD

Current Price

$14.27

Market Cap

99.5M

Sector

Technology

ML Signal

HOLD

Logo PepGen Inc.

PEPG

PepGen Inc.

HOLD

Current Price

$1.62

Market Cap

113.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RFIL
PEPG
Founded
1979
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
99.5M
113.3M
IPO Year
1996
2022

Fundamental Metrics

Financial Performance
Metric
RFIL
PEPG
Price
$14.27
$1.62
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$11.25
$11.17
AVG Volume (30 Days)
209.6K
2.6M
Earning Date
06-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
101.59
25.61
EPS
N/A
N/A
Revenue
$55,325,000.00
N/A
Revenue This Year
$9.65
N/A
Revenue Next Year
$6.40
N/A
P/E Ratio
$1,203.00
N/A
Revenue Growth
10.22
N/A
52 Week Low
$3.76
$1.01
52 Week High
$15.42
$7.80

Technical Indicators

Market Signals
Indicator
RFIL
PEPG
Relative Strength Index (RSI) 62.24 25.12
Support Level $6.11 $1.57
Resistance Level N/A $5.37
Average True Range (ATR) 0.93 0.12
MACD 0.22 0.12
Stochastic Oscillator 75.78 33.33

Price Performance

Historical Comparison
RFIL
PEPG

About RFIL RF Industries Ltd.

RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company has one operating segment. The company operates in Canada, Germany, China, the USA, and the United Kingdom, and Others.

About PEPG PepGen Inc.

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.

Share on Social Networks: